TG Therapeutics' shares jump as umbralisib wins FDA's breakthrough status
About a month after the publication of encouraging results from an early-stage study evaluating J&J’s Imbruvica in combination with its experimental drug umbralisib, TG Therapeutics on Tuesday said the drug has been granted the FDA’s breakthrough therapy status for use in patients with marginal zone lymphoma (MZL), a type of cancer with no specifically approved therapies.
The New York-based company’s stock $TGTX jumped about 12% in pre-market trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.